AKUMS
DRUGS & PHARMACEUTICALS LTD.

Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Ref: Akums/Exchange/2025-26/74

January 23, 2026

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 544222

Sub: **Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Respected Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that Akums Drugs and Pharmaceuticals Limited (the "company") has received European GMP certificates for its two facilities, Plant 1 and Plant 2, both located at Haridwar, Uttarakhand. While the certification for Plant 1 represents a renewal of its existing EU-GMP approval, Plant 2 has received EU-GMP certification for the first time.

Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided herein as **Annexure-A**.

This is for your kind information and record.

Thanking You

Yours Faithfully
For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.01.23 16:47:50 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl.: As above

AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000
CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Annexure – A

Sl. No.	Particulars	Details
1	Name of the regulatory or licensing authority	BDA – Bulgarian Drug Agency
2	Brief details of the approval / license obtained ~~/ withdrawn / surrendered~~	Akums received European GMP certificates for Plant 1 and Plant 2, situated at Haridwar (Uttarakhand). While Plant 1 is renewal of EUGMP certificate and Plant 2 is fresh certification.
3	Impact / relevance of such approval / license to the listed entity	These accreditations will enable Akums to cater to EU regulated markets; and to seek new business opportunities from EU countries and several other markets which follow EU-GMP regulations. With these approvals: • Plant 1 is authorized to manufacture and supply tablets, hard gelatine capsules, and sachet dosage forms for EU countries. • Plant 2 is authorized to manufacture and supply oral liquid formulations for EU countries. The European CDMO contract, signed by Akums in December 2024, will be serviced from Plant 2.
4	Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
5	Period for which such approval / license is~~/was~~ valid	For a period of 3 years, till October 2028
6	Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.	Not Applicable